In what was a busy day for the US pharma major, two research collaborations with Bristol Myers Squibb (NYSE: BMY) were announced yesterday.
First, Autolus Therapeutics (Nasdaq: AUTL) revealed it has entered into a deal with BMS, granting the latter access to incorporate Autolus’ proprietary RQR8 safety switch into an initial set of selected cell therapy programs on a target-by-target basis for the treatment of cancer, with an option for BMS to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs. News of the accord pushed Autolus’ shares up nearly 26% to $2.74 by close of trading.
Under the terms of the agreement, Autolus will receive an undisclosed upfront payment for access to the RQR8 safety switch for the initial set of cell therapy programs with the potential for near term option exercise fees and development milestone payments. In addition, Autolus would be entitled to receive royalties on net sales of all BMS cell therapy products that incorporate the RQR8 safety switch. Autolus' switch helps manage toxicities - a crucial safety aspect for programmed cell therapies like CAR-Ts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze